Clinical and Molecular Spectrum of PIK3CA-Related Overgrowth Syndrome: A Turkish Cohort

Yıl 2026, Cilt: 53 Sayı: 1, 203 - 211, 10.03.2026

Elifcan Taşdelen , Selin Sennaroğlu Abdulkerim Kolkıran , Melike Ataseven Kulalı , İbrahim Kaplan Tarık Alay , Şule Yeşil

https://doi.org/10.5798/dicletip.1906487

https://izlik.org/JA92UF62WP

Öz

Background: PIK3CA-related overgrowth spectrum (PROS) includes a group of mosaic overgrowth disorders caused by postzygotic gain-of-function variants in the PIK3CA gene. These variants lead to upregulation of the PI3K/AKT/mTOR signaling pathway, resulting in dysregulated cell growth, proliferation, and vasculogenesis. Disorders such as KTWS and CLOVES syndrome share overlapping clinical features such as segmental overgrowth, vascular and lymphatic malformations, and cutaneous involvement.
Methods: A cohort of five Turkish patients with clinical findings consistent with PROS was evaluated. High-depth next-generation sequencing (NGS) was performed on affected tissue samples, and the identified variants on PIK3CA gene were interpreted according to ACMG/AMP criteria. Clinical, radiological, and molecular data were integrated to assess genotype–phenotype correlations.
Results: Five distinct somatic PIK3CA variants were identified. Four were in the C-terminal helical and kinase domains—known mutational hotspots—while one variant was found in the N-terminal adaptor-binding (PI3K-ABD) domain. Four variants were missense substitutions, and one was an in-frame deletion. The mean sequencing depth was approximately 1100×, and the lowest variant allele frequency (VAF) detected was 2%. No correlation was observed between VAF and disease severity.
Conclusion: This Turkish cohort highlights the clinical and molecular heterogeneity of PROS and emphasizes the importance of tissue-targeted, high-depth sequencing in detecting low-level mosaic variants. Molecular confirmation of PIK3CA mosaicism is essential for accurate diagnosis and therapeutic decision-making. Considering the recent evidence supporting the efficacy of Alpelisib in both pediatric and adult PROS patients, early recognition and molecular characterization of these cases are critical for guiding precision therapy and improving clinical outcomes.

Anahtar Kelimeler

PIK3CA , overgrowth , segmental , somatic , mosaic

Etik Beyan

All procedures performed in this study were in accordance with the ethical standards specified in the World Medical Association Declaration of Helsinki. Ethical committee approval for the study was obtained from Ankara Etlik City Hospital Ethical Board on 17 Dec 2025 (No: AEŞH-BADEK1-2025-606).

PIK3CA-İlişkili Aşırı Büyüme Sendromlarının Klinik ve Moleküler Spektrumu: Türk Hasta Kohortu

https://izlik.org/JA92UF62WP

Öz

Arka Plan: PIK3CA-ilişkili aşırı büyüme spektrumu (PROS), PIK3CA geninde postzigotik dönemde ortaya çıkan işlev kazandırıcı (‘gain-of-function’) varyantlardan kaynaklanan mozaik aşırı büyüme sendromlarını kapsar. Bu varyantlar, PI3K/AKT/mTOR sinyal yolunun aktivasyonuna yol açarak hücre büyümesi, proliferasyonu ve damar gelişiminin düzeninin bozulmasına neden olur. Alt tiplerinden olan KTWS ve CLOVES sendromu gibi tablolar; segmental aşırı büyüme, vasküler ve lenfatik malformasyonlar ile deri tutulumunu içeren örtüşen klinik özellikler gösterir.
Yöntemler: PROS ile uyumlu klinik bulgulara sahip beş Türk hastadan oluşan bir kohort değerlendirildi. Etkilenen doku örneklerinden yüksek derinlikli yeni nesil dizileme (NGS) analizi yapıldı ve saptanan PIK3CA gen varyantları ACMG/AMP kriterlerine göre yorumlandı. Klinik, radyolojik ve moleküler veriler entegre edilerek genotip–fenotip ilişkileri incelendi.
Bulgular: Toplam beş farklı somatik PIK3CA varyantı tanımlandı. Dördü C-terminal helikal ve kinaz bölgelerinde (bilinen mutasyonel sıcak noktalar), biri ise N-terminal adaptor-bağlanma (PI3K-ABD) bölgesinde yer almaktaydı. Dört varyant ‘missense’ değişimi, biri ise çerçeve kayması oluşturmayan (‘in-frame’) delesyondu. Ortalama dizileme derinliği yaklaşık 1100× olup, saptanan en düşük varyant alel frekansı (VAF) %2 idi. VAF ile hastalık şiddeti arasında belirgin bir ilişki gözlenmedi.
Sonuç: Bu Türk kohortu, PROS’un klinik ve moleküler heterojenitesini vurgulamakta ve düşük düzeydeki mozaik varyantların saptanmasında dokuya özgü, yüksek derinlikli dizilemenin önemini ortaya koymaktadır. PIK3CA mozaisizminin moleküler olarak doğrulanması, doğru tanı ve uygun tedavi seçimi açısından kritik öneme sahiptir. Hem pediatrik hem de erişkin PROS olgularında Alpelisib tedavisinin etkinliğini destekleyen güncel veriler göz önüne alındığında, bu hastaların erken tanınması ve moleküler olarak karakterize edilmesi, hedefe yönelik tedavi ve klinik sonuçların iyileştirilmesi açısından büyük önem taşımaktadır.

Anahtar Kelimeler

PIK3CA , aşırı büyüme , segmental , somatik , mozaik

Kaynakça

• 1.Mirzaa G, Graham JM Jr, Keppler-Noreuil K.PIK3CA-Related Overgrowth Spectrum. In:GeneReviews®. University of Washington, Seattle,Seattle (WA); 1993. PMID: 23946963.
• 2.Keppler-Noreuil KM, Rios JJ, Parker VE, et al.PIK3CA-related overgrowth spectrum (PROS):diagnostic and testing eligibility criteria, differentialdiagnosis, and evaluation. Am J Med Genet A.2015;167A(2):287-95.
• 3.Kuentz P, St-Onge J, Duffourd Y, et al. Moleculardiagnosis of PIK3CA-related overgrowth spectrum(PROS) in 162 patients and recommendations forgenetic testing. Genet Med. 2017;19(9):989-97.
• 4.Lindhurst MJ, Parker VE, Payne F, et al. Mosaicovergrowth with fibroadipose hyperplasia is causedby somatic activating mutations in PIK3CA. NatGenet. 2012;44(8):928-33.
• 5.Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, et al.Clinical delineation and natural history of thePIK3CA-related overgrowth spectrum. Am J MedGenet A. 2014;164A(7):1713-33.
• 6.Mirzaa G, Timms AE, Conti V, et al. PIK3CA-associated developmental disorders exhibit distinctclasses of mutations with variable expression andtissue distribution. JCI Insight. 2016;1(9):e87623.
• 7.Sapp JC, Turner JT, van de Kamp JM, et al. Newlydelineated syndrome of congenital lipomatousovergrowth, vascular malformations, and epidermalnevi (CLOVE syndrome) in seven patients. Am J MedGenet A. 2007;143A(24):2944-58.
• 8.Sasaki Y, Ishikawa K, Hatanaka KC, et al. Targetednext-generation sequencing for detection of PIK3CAmutations in archival tissues from patients withKlippel-Trenaunay syndrome in an Asian population: List the full names and institutional addresses forall authors. Orphanet J Rare Dis. 2023;18(1):270.
• 9.Yeung KS, Ip JJ, Chow CP, et al. Somatic PIK3CAmutations in seven patients with PIK3CA-relatedovergrowth spectrum. Am J Med Genet A. 2017;173(4):978-84.
• 10.Brouillard P, Schlögel MJ, Homayun Sepehr N, etal. Non-hotspot PIK3CA mutations are morefrequent in CLOVES than in common or combinedlymphatic malformations. Orphanet J Rare Dis.2021;16(1):267.
• 11.Zhang B, He R, Xu Z, et al. Somatic mutationspectrum of a Chinese cohort of pediatrics withvascular malformations. Orphanet J Rare Dis.2023;18(1):261.
• 12.Keppler-Noreuil KM, Lozier J, Oden N, et al.Thrombosis risk factors in PIK3CA-relatedovergrowth spectrum and Proteus syndrome. Am JMed Genet C Semin Med Genet. 2019;181(4):571-81.
• 13.Madsen RR, Vanhaesebroeck B, Semple RK.Cancer-Associated PIK3CA Mutations inOvergrowth Disorders. Trends Mol Med.2018;24(10):856-70.
• 14.Mussa A, Leoni C, Iacoviello M, et al. Genotypesand phenotypes heterogeneity in PIK3CA-relatedovergrowth spectrum and overlapping conditions:150 novel patients and systematic review of 1007patients with PIK3CA pathogenetic variants. J MedGenet. 2023;60(2):16373.
• 15.Gökpınar İli E, Taşdelen E, Durmaz CD, et al.Phenotypic and molecular characterization of fivepatients with PIK3CA-related overgrowth spectrum(PROS). Am J Med Genet A. 2022;188(6):1792-800.
• 16.Park HJ, Shin CH, Yoo WJ, et al. Detailed analysisof phenotypes and genotypes in megalencephaly-capillary malformation-polymicrogyria syndromecaused by somatic mosaicism of PIK3CA mutations.Orphanet J Rare Dis. 2020;15(1):205.
• 17.Canaud G, Lopez Gutierrez JC, Irvine AD, et al.Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet Med.2023;25(12):100969.